These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1069 related items for PubMed ID: 16367883

  • 1. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (The 1-2-3 study).
    Garber AJ, Wahlen J, Wahl T, Bressler P, Braceras R, Allen E, Jain R.
    Diabetes Obes Metab; 2006 Jan; 8(1):58-66. PubMed ID: 16367883
    [Abstract] [Full Text] [Related]

  • 2. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 3. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

  • 4. Biphasic insulin aspart 30 plus metformin: an effective combination in type 2 diabetes.
    Kvapil M, Swatko A, Hilberg C, Shestakova M.
    Diabetes Obes Metab; 2006 Jan; 8(1):39-48. PubMed ID: 16367881
    [Abstract] [Full Text] [Related]

  • 5. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
    Cucinotta D, Smirnova O, Christiansen JS, Kanc K, le Devehat C, Wojciechowska M, López de la Torre M, Liebl A.
    Diabetes Obes Metab; 2009 Jul; 11(7):700-8. PubMed ID: 19476479
    [Abstract] [Full Text] [Related]

  • 6. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial.
    Liebl A, Prager R, Binz K, Kaiser M, Bergenstal R, Gallwitz B, PREFER Study Group.
    Diabetes Obes Metab; 2009 Jan; 11(1):45-52. PubMed ID: 18643839
    [Abstract] [Full Text] [Related]

  • 7. Starting insulin therapy in type 2 diabetes: twice-daily biphasic insulin Aspart 30 plus metformin versus once-daily insulin glargine plus glimepiride.
    Kann PH, Wascher T, Zackova V, Moeller J, Medding J, Szocs A, Mokan M, Mrevlje F, Regulski M.
    Exp Clin Endocrinol Diabetes; 2006 Oct; 114(9):527-32. PubMed ID: 17115351
    [Abstract] [Full Text] [Related]

  • 8. Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs.
    Raskin P, Allen E, Hollander P, Lewin A, Gabbay RA, Hu P, Bode B, Garber A, INITIATE Study Group.
    Diabetes Care; 2005 Feb; 28(2):260-5. PubMed ID: 15677776
    [Abstract] [Full Text] [Related]

  • 9. Attainment of glycaemic goals by step-up therapy with biphasic insulin aspart-70/30 in Japanese type 2 diabetic patients.
    Hosoi Y, Ohtani K, Shimizu H, Kashima K, Sato N, Akiyama H, Mori M.
    Endocr J; 2011 Feb; 58(2):131-5. PubMed ID: 21186332
    [Abstract] [Full Text] [Related]

  • 10. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study.
    Wenying Y, Benroubi M, Borzi V, Gumprecht J, Kawamori R, Shaban J, Shah S, Shestakova M, Ligthelm R, Valensi P, IMPROVE Study Group Expert Panel.
    Curr Med Res Opin; 2009 Nov; 25(11):2643-54. PubMed ID: 19751116
    [Abstract] [Full Text] [Related]

  • 11. Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets - the TITRATE study.
    Blonde L, Merilainen M, Karwe V, Raskin P, TITRATE Study Group.
    Diabetes Obes Metab; 2009 Jun; 11(6):623-31. PubMed ID: 19515182
    [Abstract] [Full Text] [Related]

  • 12. Self-titration of biphasic insulin aspart 30/70 improves glycaemic control and allows easy intensification in a Dutch clinical practice.
    Ligthelm RJ.
    Prim Care Diabetes; 2009 May; 3(2):97-102. PubMed ID: 19285933
    [Abstract] [Full Text] [Related]

  • 13. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes.
    Hollander P, Cooper J, Bregnhøj J, Pedersen CB.
    Clin Ther; 2008 Nov; 30(11):1976-87. PubMed ID: 19108786
    [Abstract] [Full Text] [Related]

  • 14. A comparison of biphasic insulin aspart and insulin glargine administered with oral antidiabetic drugs in type 2 diabetes mellitus--a systematic review and meta-analysis.
    Rys P, Wojciechowski P, Siejka S, Małecki P, Hak L, Malecki MT.
    Int J Clin Pract; 2014 Mar; 68(3):304-13. PubMed ID: 24471814
    [Abstract] [Full Text] [Related]

  • 15. Clinical effectiveness of biphasic insulin aspart 30:70 versus biphasic human insulin 30 in UK general clinical practice: a retrospective database study.
    Morgan CL, Evans M, Toft AD, Jenkins-Jones S, Poole CD, Currie CJ.
    Clin Ther; 2011 Jan; 33(1):27-35. PubMed ID: 21397771
    [Abstract] [Full Text] [Related]

  • 16. A comparison of twice-daily biphasic insulin aspart 70/30 and once-daily insulin glargine in persons with type 2 diabetes mellitus inadequately controlled on basal insulin and oral therapy: a randomized, open-label study.
    Ligthelm RJ, Gylvin T, DeLuzio T, Raskin P.
    Endocr Pract; 2011 Jan; 17(1):41-50. PubMed ID: 20713345
    [Abstract] [Full Text] [Related]

  • 17. Risk for nocturnal hypoglycemia with biphasic insulin aspart 30 compared with biphasic human insulin 30 in adults with type 2 diabetes mellitus: a meta-analysis.
    Davidson JA, Liebl A, Christiansen JS, Fulcher G, Ligthelm RJ, Brown P, Gylvin T, Kawamori R.
    Clin Ther; 2009 Aug; 31(8):1641-51. PubMed ID: 19808125
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of biphasic insulin aspart in patients with type 2 diabetes.
    Halimi S, Raskin P, Liebl A, Kawamori R, Fulcher G, Yan G.
    Clin Ther; 2005 Aug; 27 Suppl B():S57-74. PubMed ID: 16519038
    [Abstract] [Full Text] [Related]

  • 19. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results.
    Nobels F, D'Hooge D, Crenier L.
    Curr Med Res Opin; 2012 Jun; 28(6):1017-26. PubMed ID: 22612579
    [Abstract] [Full Text] [Related]

  • 20. Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes.
    Shah S, Das AK, Kumar A, Unnikrishnan AG, Kalra S, Baruah MP, Ganapathi B, Sahay RK.
    Adv Ther; 2009 Mar; 26(3):325-35. PubMed ID: 19252828
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 54.